Abstract
Omega-3 fatty acids are essential substances for the development and function of human organism. They cannot be synthesized in humans, and consequently have to be acquired from food, almost exclusively from fish. Omega-3 fatty acids exert potent anti-inflammatory and anti-atherosclerotic actions by interfering with the metabolism of arachidonic acid, modifying lipid composition (mainly lowering triglycerides), improving hemodynamics and reducing cardiac hypertrophy. Recently, clinical and experimental studies demonstrated an anti-arrhythmic effect and a significant impact on survival after myocardial infarction (MI). It follows that omega-3 fatty acids have been widely accepted for clinical use in patients with dyslipidemia or with atherosclerotic disease and in survivors of acute MI. This review briefly explores the metabolic mechanisms and the clinical effects of this class of substances and considers their use in patients with cardiovascular disease.
Keywords: Omega-3, lipids, cardiovascular disease, inflammation, atherosclerosis, arrhythmias
Current Vascular Pharmacology
Title: Cardiovascular Effects of Omega-3 Free Fatty Acids.
Volume: 5 Issue: 2
Author(s): Francesco Biscione, Carlo Pignalberi, Alessandro Totteri, Francesco Messina and Giuliano Altamura
Affiliation:
Keywords: Omega-3, lipids, cardiovascular disease, inflammation, atherosclerosis, arrhythmias
Abstract: Omega-3 fatty acids are essential substances for the development and function of human organism. They cannot be synthesized in humans, and consequently have to be acquired from food, almost exclusively from fish. Omega-3 fatty acids exert potent anti-inflammatory and anti-atherosclerotic actions by interfering with the metabolism of arachidonic acid, modifying lipid composition (mainly lowering triglycerides), improving hemodynamics and reducing cardiac hypertrophy. Recently, clinical and experimental studies demonstrated an anti-arrhythmic effect and a significant impact on survival after myocardial infarction (MI). It follows that omega-3 fatty acids have been widely accepted for clinical use in patients with dyslipidemia or with atherosclerotic disease and in survivors of acute MI. This review briefly explores the metabolic mechanisms and the clinical effects of this class of substances and considers their use in patients with cardiovascular disease.
Export Options
About this article
Cite this article as:
Biscione Francesco, Pignalberi Carlo, Totteri Alessandro, Messina Francesco and Altamura Giuliano, Cardiovascular Effects of Omega-3 Free Fatty Acids., Current Vascular Pharmacology 2007; 5 (2) . https://dx.doi.org/10.2174/157016107780368334
DOI https://dx.doi.org/10.2174/157016107780368334 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
TNF Receptor: Fc Fusion Protein Downregulates RANKL/OPG Ratio by Inhibiting CXCL16/CXCR6 in Active Ankylosing Spondylitis
Current Pharmaceutical Biotechnology Microalbuminuria: A Neglected Cardiovascular Risk Factor in Non-diabetic Individuals?
Current Pharmaceutical Design Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients
Current Vascular Pharmacology The Role of High-Density Lipoprotein Cholesterol in the Prevention and Possible Treatment of Cardiovascular Diseases
Current Molecular Medicine Advanced Glycation End Products (AGEs) and Cardiovascular Disease (CVD) in Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Developing the Evidence Base for Cancer Chemoprevention: Use of Meta-Analysis
Current Drug Targets Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders
Current Drug Metabolism Super-Resolution Based Enhancement of Cardiac MR Images
Current Medical Imaging Telomerase Therapeutics for Degenerative Diseases
Current Molecular Medicine Fitness or Fatness: The Debate Continues for AMP-Activated Protein Kinase in Heart Function
Current Cardiology Reviews Electroanalytical Methods for Determination of Calcium Channel Blockers
Current Analytical Chemistry The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders Estrogen Receptors as Targets for Drug Development for Breast Cancer, Osteoporosis and Cardiovascular Diseases
Current Cancer Drug Targets Inhibitory Effects of Some Bryophytes on Glutathione-S -Transferase
Current Enzyme Inhibition Noninvasive Diagnosis of Chemotherapy Related Cardiotoxicity
Current Cardiology Reviews Resveratrol and Cardiovascular Disease
Current Nutrition & Food Science Neurotoxicity by Synthetic Androgen Steroids: Oxidative Stress, Apoptosis, and Neuropathology: A Review
Current Neuropharmacology Mass Spectrometric Analysis of F2-Isoprostanes: Markers and Mediators in Human Disease
Current Pharmaceutical Analysis Tissue Protective and Anti-Fibrotic Actions of Suramin: New Uses of an Old Drug
Current Clinical Pharmacology The Right Ventricle: Biologic Insights and Response to Disease: Updated
Current Cardiology Reviews